Sign In
Buy BMRN
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
Car-T Cells Might Hold The Secret To The Fountain Of Youth
12:43pm, Thursday, 18'th Jun 2020
In mice, they can eliminate the cells partly responsible for many diseases of aging, researchers report. In other news: hemophilia gene therapy and concerns over AbbVie-Allergan merger.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Armata Pharmaceuticals
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
12:34pm, Thursday, 18'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) * Adverum Biotechnologies Inc (NASDAQ: ADVM) * Affim
BioMarin Pharmaceutical’s (BMRN) “Buy” Rating Reaffirmed at SunTrust Banks
03:44am, Thursday, 18'th Jun 2020
BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “buy” rating restated by SunTrust Banks in a note issued to investors on Wednesday, TipRanks reports. They presently have a $109.00 price ob
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
12:00am, Thursday, 18'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors | MarketScreener
08:06pm, Wednesday, 17'th Jun 2020uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
08:05pm, Wednesday, 17'th Jun 2020
~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~ LEXINGTON, Mass. and AMSTERDAM, June 17, 2020 -- uniQure N.V. (NASDAQ: QURE), a leading gene.
BioMarin’s hemophilia gene therapy still prevents bleeding at four years
01:20pm, Wednesday, 17'th Jun 2020
BioMarin’s experimental hemophilia gene therapy, expected to be approved in the U.S. this year, still prevents bleeding in patients treated four years ago.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigati
SAN RAFAEL, Calif., June 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 s
Novo Nordisk A/S : Courts Across The Country Continue To Address Trade Secrets Issues | MarketScreener
08:13am, Tuesday, 16'th Jun 2020Hauser and Wirth Opens Up Its Website to Host an Indie Art Fair That Had to Cancel Its Basel Edition | artnet News
06:00am, Tuesday, 16'th Jun 2020
The move is the latest effort by a mega-gallery to host struggling smaller upstarts online—and gain additional eyeballs in the process.
Praemium eyes expansion of Fatca-compliant offering
03:47pm, Monday, 15'th Jun 2020
Many firms and financial institutions have been turning US citizens away due to reporting burden #dunhillfinancial #fatca #investments
REGN vs. BMRN: Which Stock Is the Better Value Option?
03:40pm, Monday, 15'th Jun 2020
REGN vs. BMRN: Which Stock Is the Better Value Option?
